CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionCurrent ratio is 44.83×, higher than 95% of its Medical Devices peers (median 3.87×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.17%
Annual Rate
CNY 0.03Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Aug 6, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
2.79BCNY417.21M · vs all stocks (USD)
Trailing P/E
300.33xvs Medical Devices peers
Revenue (TTM)
227.76MCNY34.00M · vs all stocks (USD)
Profit Margin
3.78%vs Medical Devices peers
Beta
0.5940xvs all stocks
52-Week Change
-23.68%vs all stocks
Forward Annual Dividend Yield
0.17%vs all stocks
Market Capitalization
2.79BCNY417.21M · vs all stocks (USD)
Enterprise Value
1.50BCNY223.52M · vs all stocks (USD)
Trailing P/E
300.33xvs Medical Devices peers
Price to Sales (TTM)
10.84xvs Medical Devices peers
Price to Book (MRQ)
1.69xvs Medical Devices peers
Enterprise to Revenue
6.57xvs Medical Devices peers
Enterprise to EBITDA
89.08xvs Medical Devices peers
Gross Margin
65.34%vs Medical Devices peers
Profit Margin
3.78%vs Medical Devices peers
Operating Margin
-5.63%vs Medical Devices peers
Return on Assets (TTM)
-0.20%vs Medical Devices peers
Return on Equity (TTM)
0.36%vs Medical Devices peers
Revenue (TTM)
227.76MCNY34.00M · vs all stocks (USD)
Revenue per Share (TTM)
1.62CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-3.80%vs Medical Devices peers
Gross Profit (TTM)
156.17MCNY23.31M · vs all stocks (USD)
EBITDA (TTM)
18.72MCNY2.79M · vs all stocks (USD)
Net Income (TTM)
8.62MCNY1.29M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-80.60%vs Medical Devices peers
Operating Cash Flow (TTM)
-7.72MCNY-1.15M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-34.59MCNY-5.16M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0300CNYUpdated Sep 22, 2026Forward Annual Dividend Yield
0.17%vs all stocks
Trailing Annual Dividend Rate
0.0300CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.18%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
12.75MCNYFY2025 · Dec 31, 2025Revenue
223.74MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
70.12MCNYFY2025 · Dec 31, 2025Gross Profit
153.62MCNYFY2025 · Dec 31, 2025Operating Income
-3.79MCNY-566.08K · vs all stocks (USD)
Pre-tax Income
12.29MCNYFY2025 · Dec 31, 2025Income Tax Expense
2.79MCNYFY2025 · Dec 31, 2025Net Income
9.50MCNYFY2025 · Dec 31, 2025EBIT
14.66MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
18.72MCNYFY2025 · Dec 31, 2025Research & Development
39.25MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
42.21MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.30MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
356.50KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.38MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1000CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
138.39MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
138.39MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
9.50MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.34MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
32.75MCNYFY2025 · Dec 31, 2025Free Cash Flow
3.83MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
169.06MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
9.50MCNYFY2025 · Dec 31, 2025Other Non-cash Items
11.81MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
29.99MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-18.55MCNYFY2025 · Dec 31, 2025Capital Expenditures
-28.93MCNYFY2025 · Dec 31, 2025Purchase of Investments
-30.00MCNYFY2025 · Dec 31, 2025Sale of Investments
25.12MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-33.80MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-4.69MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.28MCNYFY2025 · Dec 31, 2025Other Financing Charges
13.24MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
6.26MCNYFY2025 · Dec 31, 2025Shares Outstanding
137.01MSharesUpdated Sep 22, 2026Float Shares
99.42MSharesUpdated Sep 22, 2026% Held by Insiders
33.74%vs all stocks
% Held by Institutions
4.57%vs all stocks
Total Cash (MRQ)
1.01BCNY151.09M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.39CNYUpdated Sep 22, 2026Total Debt (MRQ)
29.52MCNY4.41M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0204xvs Medical Devices peers
Current Ratio (MRQ)
44.83xvs Medical Devices peers
Book Value per Share (MRQ)
10.69CNYUpdated Sep 22, 2026Total Assets
1.56BCNY233.44M · vs all stocks (USD)
Total Current Assets
1.22BCNYFY2025 · Dec 31, 2025Total Liabilities
116.52MCNYFY2025 · Dec 31, 2025Total Non-current Assets
340.35MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
34.54MCNYFY2025 · Dec 31, 2025Total Current Liabilities
81.98MCNYFY2025 · Dec 31, 2025Cash
169.07MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
169.07MCNYFY2025 · Dec 31, 2025Other Short-term Investments
913.63MCNYFY2025 · Dec 31, 2025Accounts Receivable
27.46MCNYFY2025 · Dec 31, 2025Inventory
76.94MCNYFY2025 · Dec 31, 2025Accounts Payable
12.41MCNYFY2025 · Dec 31, 2025Short-term Debt
36.90MCNYFY2025 · Dec 31, 2025Other Current Liabilities
735.06KCNYFY2025 · Dec 31, 2025Long-term Debt
11.03MCNYFY2025 · Dec 31, 2025Common Stock (Book)
137.01MCNYFY2025 · Dec 31, 2025Retained Earnings
264.10MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.45BCNY216.05M · vs all stocks (USD)
52-Week Low
12.94CNYUpdated Sep 22, 202652-Week High
29.77CNYUpdated Sep 22, 202652-Week Change
-23.68%vs all stocks
Beta
0.5940xvs all stocks
50-Day MA
15.20CNYUpdated Sep 22, 2026200-Day MA
19.13CNYUpdated Sep 22, 2026Avg 10-Day Volume
4.31MSharesUpdated Sep 22, 2026Avg 30-Day Volume
3.52MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.0600CNYUpdated Sep 22, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 44.83×, higher than 95% of its Medical Devices peers (median 3.87×)Significant
Current ratio: 44.83Industry median: 3.87Industry P95: 12.55Peers compared: 102
P/E ratio is 300.33×, higher than 95% of its Medical Devices peers (median 31.99×)Significant
P/E ratio: 300.333Industry median: 31.99Industry P95: 189.554Peers compared: 102
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 1,286,481.704Operating Cash Flow (USD, TTM): -1,151,888.229
High gross margins eroded by operating costsNotable
Gross Margin: 0.65Profit Margin: 0.04
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Orum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Canopy Growth Corporation
Tier 1ProductionApproval-Gated PipelineFlowRule
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Fengyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Suzhou Weizhixiang Food Co., Ltd.
1 interpretationLow-Leverage Liquidity Configuration
Finolex Cables Ltd.
1 interpretationLow-Leverage Liquidity Configuration
Fulgent Genetics Inc.
1 interpretationLow-Leverage Liquidity Configuration